{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T07:01:49Z","timestamp":1764745309968,"version":"3.46.0"},"reference-count":37,"publisher":"Touch Medical Media, Ltd.","issue":"1","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This article is published under the Creative Commons Attribution Non-commercial License."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"abstract":"<p\/>","DOI":"10.17925\/ee.2021.17.1.33","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T05:12:57Z","timestamp":1624511577000},"page":"33","source":"Crossref","is-referenced-by-count":0,"title":["Potential Role of Dexamphetamine in the Treatment of Non-alcoholic Fatty Liver Disease: Hopes and Pitfalls"],"prefix":"10.17925","volume":"17","author":[{"given":"CS","family":"Gautam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Pharmacology, Government Medical College and Hospital, Chandigarh, India","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jatin","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandeep","family":"Singla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Pharmacology, Government Medical College and Hospital, Chandigarh, India","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilmjot Kaur","family":"Tiwana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Government Medical College and Rajindra Hospital, Patiala, India","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harmanjit","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Pharmacology, Government Medical College and Hospital, Chandigarh, India","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7274","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.\n                      Gastroenterology\n                      . 2012;142:1592\u2013609.","DOI":"10.1053\/j.gastro.2012.04.001"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.\n                      Hepatology\n                      . 2018;67:328\u201357.","DOI":"10.1002\/hep.29367"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.\n                      Gastroenterology\n                      . 2011;141:1249\u201353.","DOI":"10.1053\/j.gastro.2011.06.061"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Duseja A. Nonalcoholic fatty liver disease in India - a lot done, yet more required!\n                      Indian J Gastroenterol\n                      . 2010;29:217\u201325.","DOI":"10.1007\/s12664-010-0069-1"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease- Meta-analytic assessment of prevalence, incidence and outcomes.\n                      Hepatology\n                      . 2016;64:73\u201384.","DOI":"10.1002\/hep.28431"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease.\n                      Gastroenterology\n                      . 2020;158:1999\u20132014.","DOI":"10.1053\/j.gastro.2019.11.312"},{"key":"ref7","unstructured":"Medical Xpress. MAFLD: A new name and definition brings hope for patients with fatty liver disease. Available at: https:\/\/medicalxpress.com\/news\/2020-03-mafld-definition-patients-fatty-liver.html (accessed 28 January 2021)."},{"key":"ref8","unstructured":"Kalra S, Vithalani M, Gulati G, et al. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT).\n                      J Assoc Physicians India\n                      . 2013;61:448\u201353."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis.\n                      Hepatology\n                      . 2017;65:1557\u201365.","DOI":"10.1002\/hep.29085"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Geier S, Rau M. Emerging therapies for NASH - the future is now.\n                      Expert Rev Clin Pharmacol\n                      . 2017;10:467\u20139.","DOI":"10.1080\/17512433.2017.1305269"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss.\n                      Hepatology\n                      . 2004;39:1647\u201354.","DOI":"10.1002\/hep.20251"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Bhat G, Baba CS, Pandey A, et al. Life style modification improves insulin resistance and liver histology in patients with non-alcoholic fatty liver disease.\n                      World J Hepatol\n                      . 2012;4:209\u201317.","DOI":"10.4254\/wjh.v4.i7.209"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease.\n                      Hepatology\n                      . 2010;52:79\u2013104.","DOI":"10.1002\/hep.23623"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus.\n                      Nat Rev Gastroenterol Hepatol\n                      . 2017;14:32\u201342.","DOI":"10.1038\/nrgastro.2016.147"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial.\n                      Ann Intern Med\n                      . 2016;165:305\u201315.","DOI":"10.7326\/M15-1774"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Li Y, Liu L, Wang B, et al. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis.\n                      Biomed Rep\n                      . 2013;1:57\u201364.","DOI":"10.3892\/br.2012.18"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Makri E, Cholongitas E, Tziomalos K. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.\n                      World J Gastroenterol\n                      . 2016;22:9039\u201343.","DOI":"10.3748\/wjg.v22.i41.9039"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.\n                      Lancet\n                      . 2015;385:956-65. [Erratum in: Lancet. 2015;385:946. Erratum in: Lancet. 2016;387:1618.]","DOI":"10.1016\/S0140-6736(14)61933-4"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.\n                      Gastroenterology\n                      . 2013;145:574\u201382.","DOI":"10.1053\/j.gastro.2013.05.042"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Rizzo R, Gulisano M. Clinical pharmacology of comorbid attention deficit hyperactivity disorder in Tourette syndrome.\n                      Int Rev Neurobiol\n                      . 2013;112:415\u201344.","DOI":"10.1016\/B978-0-12-411546-0.00014-7"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Stemmer K, M\u00fcller TD, DiMarchi RD, et al. CNS-targeting pharmacological interventions for the metabolic syndrome.\n                      J Clin Invest\n                      . 2019;129:4058\u201371.","DOI":"10.1172\/JCI129195"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present a pharmacological and clinical perspective.\n                      J Psychopharmacol\n                      . 2013;27:479\u201396.","DOI":"10.1177\/0269881113482532"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Angrist B, Corwin J, Bartlik B, Cooper T. Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects.\n                      Biol Psychiatry\n                      . 1987;22:1357\u201368.","DOI":"10.1016\/0006-3223(87)90070-9"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Haddock CK, Poston WS, Dill PL, et al. Pharmacotherapy form obesity: a quantitative analysis of four decades of published randomized clinical trials.\n                      Int J Obes Relat Metab Disord\n                      . 2002;26:262\u201373.","DOI":"10.1038\/sj.ijo.0801889"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Schrantee A, Tremoleda JL, Wylezinska-Arridge M, et al. Repeated dexamphetamine treatment alters the dopaminergic system and increases the phMRI response to methylphenidate.\n                      PLoS One\n                      . 2017;12:e0172776.","DOI":"10.1371\/journal.pone.0172776"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Ghazala S, Bilal J, Ross E, et al. Low-dose d-amphetamine induced regression of liver fat deposits in Dercum disease.\n                      Am J Med\n                      . 2018;131:705\u20138.","DOI":"10.1016\/j.amjmed.2017.12.026"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Smail D, O'Connell MA, Zacharin MR. Dexamphetamine use for management of obesity and hypersomnolence following hypothalamic injury.\n                      J Pediatr Endocrinol Metab\n                      . 2006;19:129\u201334.","DOI":"10.1515\/JPEM.2006.19.2.129"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Denzer C, Denzer F, Lennerz BS, et al. Treatment of hypothalamic obesity with dextroamphetamine: a case series.\n                      Obes Facts\n                      . 2019;12:91\u2013102.","DOI":"10.1159\/000495851"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Mason PW, Krawiecki N, Meacham LR. The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma.\n                      Arch Pediatr Adolesc Med\n                      . 2002;156:887\u201392.","DOI":"10.1001\/archpedi.156.9.887"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Poulton AS, Hibbert EJ, Champion BL, et al. Piloting a new approach to the treatment of obesity using dexamphetamine.\n                      Front Endocrinol (Lausanne)\n                      . 2015;6:14.","DOI":"10.3389\/fendo.2015.00014"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Decara JM, Pav\u00f3n FJ, Su\u00e1rez J, et al. Treatment with a novel oleic-acid dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats.\n                      Dis Model Mech\n                      . 2015;8:1213\u201325.","DOI":"10.1242\/dmm.019919"},{"key":"ref32","unstructured":"Sabuncu T, Nazligul Y, Karaoglanoglu M, et al. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.\n                      Rom J Gastroenterol\n                      . 2003;12:189\u201392."},{"key":"ref33","unstructured":"ClinicalTrials.gov. Effectiveness and Tolerability of Phentermine in Patients Under Bariatric Surgery. ClinicalTrials.gov Identifier: NCT03849729. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03849729 (accessed 28 January 2021)."},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Long D, Young J.\n                      Dexamphetamine treatment in stroke\n                      .\n                      QJM\n                      . 2003;96:673\u201385.","DOI":"10.1093\/qjmed\/hcg113"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Williams RJ, Goodale LA, Shay-Fiddler MA, et al. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents.\n                      Am J Addict\n                      . 2004;13:381\u20139.","DOI":"10.1080\/10550490490483053"},{"key":"ref36","unstructured":"DEXEDRINE\u00ae (dextroamphetamine sulfate) SPANSULE\u00ae sustained-release capsules and Tablets. Prescribing information. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/017078s042lbl.pdf (accessed 28 January 2021)."},{"key":"ref37","unstructured":"Drugs.com. Amphetamine\/dextroamphetamine Drug Interactions. Available at: www.drugs.com\/drug-interactions\/amphetamine-dextroamphetamine.html (accessed 28 January 2021)."}],"container-title":["touchREVIEWS in Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/touchendocrinology.com\/liver-disorders\/journal-articles\/potential-role-of-dexamphetamine-in-the-treatment-of-non-alcoholic-fatty-liver-disease-hopes-and-pitfalls\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:59:43Z","timestamp":1764745183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.touchendocrinology.com\/liver-disorders\/journal-articles\/potential-role-of-dexamphetamine-in-the-treatment-of-non-alcoholic-fatty-liver-disease-hopes-and-pitfalls\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"alternative-id":["EE.2021.17.1.33"],"URL":"https:\/\/doi.org\/10.17925\/ee.2021.17.1.33","relation":{},"ISSN":["1758-3772"],"issn-type":[{"type":"print","value":"1758-3772"}],"subject":[],"published":{"date-parts":[[2021]]}}}